Amalgamated Bank Sells 1,082 Shares of Fulgent Genetics, Inc. (NASDAQ:FLGT)

Amalgamated Bank trimmed its position in shares of Fulgent Genetics, Inc. (NASDAQ:FLGTFree Report) by 13.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 7,040 shares of the company’s stock after selling 1,082 shares during the period. Amalgamated Bank’s holdings in Fulgent Genetics were worth $204,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Cambridge Investment Research Advisors Inc. lifted its holdings in Fulgent Genetics by 7.0% during the 3rd quarter. Cambridge Investment Research Advisors Inc. now owns 10,572 shares of the company’s stock worth $283,000 after buying an additional 693 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Fulgent Genetics by 20.3% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,902 shares of the company’s stock valued at $131,000 after buying an additional 828 shares in the last quarter. Victory Capital Management Inc. increased its position in shares of Fulgent Genetics by 31.3% in the 3rd quarter. Victory Capital Management Inc. now owns 71,810 shares of the company’s stock valued at $1,920,000 after buying an additional 17,103 shares in the last quarter. Versor Investments LP increased its holdings in Fulgent Genetics by 184.7% during the 3rd quarter. Versor Investments LP now owns 23,380 shares of the company’s stock worth $625,000 after purchasing an additional 15,167 shares in the last quarter. Finally, Illinois Municipal Retirement Fund bought a new position in Fulgent Genetics during the 3rd quarter worth about $317,000. 48.06% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Separately, Piper Sandler decreased their price objective on Fulgent Genetics from $28.00 to $25.00 and set a “neutral” rating for the company in a report on Wednesday, March 6th.

View Our Latest Stock Analysis on Fulgent Genetics

Fulgent Genetics Stock Performance

Shares of NASDAQ:FLGT opened at $21.35 on Thursday. Fulgent Genetics, Inc. has a 52-week low of $19.88 and a 52-week high of $44.09. The company has a market capitalization of $638.79 million, a P/E ratio of -3.83 and a beta of 1.43. The company has a 50-day simple moving average of $21.34 and a 200 day simple moving average of $24.71.

Fulgent Genetics (NASDAQ:FLGTGet Free Report) last issued its earnings results on Wednesday, February 28th. The company reported ($0.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.63) by $0.61. The business had revenue of $70.51 million during the quarter, compared to the consensus estimate of $67.14 million. Fulgent Genetics had a negative net margin of 57.72% and a negative return on equity of 2.92%. As a group, equities analysts forecast that Fulgent Genetics, Inc. will post -2.12 earnings per share for the current year.

Fulgent Genetics Company Profile

(Free Report)

Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.

Read More

Institutional Ownership by Quarter for Fulgent Genetics (NASDAQ:FLGT)

Receive News & Ratings for Fulgent Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fulgent Genetics and related companies with MarketBeat.com's FREE daily email newsletter.